Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human neural progenitor cell models to study the antiviral effects and neuroprotective potential of approved and investigational human cytomegalovirus inhibitors.
Trevisan M, Pianezzola A, Onorati M, Apolloni L, Pistello M, Arav-Boger R, Palù G, Mercorelli B, Loregian A. Trevisan M, et al. Among authors: loregian a. Antiviral Res. 2024 Mar;223:105816. doi: 10.1016/j.antiviral.2024.105816. Epub 2024 Jan 28. Antiviral Res. 2024. PMID: 38286212 Free article.
Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
Zhang J, Murugan NA, Tian Y, Bertagnin C, Fang Z, Kang D, Kong X, Jia H, Sun Z, Jia R, Gao P, Poongavanam V, Loregian A, Xu W, Ma X, Ding X, Huang B, Zhan P, Liu X. Zhang J, et al. Among authors: loregian a. J Med Chem. 2018 Nov 21;61(22):9976-9999. doi: 10.1021/acs.jmedchem.8b01065. Epub 2018 Nov 6. J Med Chem. 2018. PMID: 30365885
Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
Zhang J, Poongavanam V, Kang D, Bertagnin C, Lu H, Kong X, Ju H, Lu X, Gao P, Tian Y, Jia H, Desta S, Ding X, Sun L, Fang Z, Huang B, Liang X, Jia R, Ma X, Xu W, Murugan NA, Loregian A, Huang B, Zhan P, Liu X. Zhang J, et al. Among authors: loregian a. J Med Chem. 2018 Jul 26;61(14):6379-6397. doi: 10.1021/acs.jmedchem.8b00929. Epub 2018 Jul 16. J Med Chem. 2018. PMID: 29965752
Residues of human cytomegalovirus DNA polymerase catalytic subunit UL54 that are necessary and sufficient for interaction with the accessory protein UL44.
Loregian A, Appleton BA, Hogle JM, Coen DM. Loregian A, et al. J Virol. 2004 Jan;78(1):158-67. doi: 10.1128/jvi.78.1.158-167.2004. J Virol. 2004. PMID: 14671097 Free PMC article.
The human cytomegalovirus DNA polymerase contains a catalytic subunit, UL54, and an accessory protein, UL44. Recent studies suggested that UL54 might interact via its extreme C terminus with UL44 (A. ...To address this hypothesis, we quantitatively measured the bind …
The human cytomegalovirus DNA polymerase contains a catalytic subunit, UL54, and an accessory protein, UL44. Recent studies suggested …
Identification of C5-NH2 Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.
Ju H, Murugan NA, Hou L, Li P, Guizzo L, Zhang Y, Bertagnin C, Kong X, Kang D, Jia R, Ma X, Du R, Poongavanam V, Loregian A, Huang B, Liu X, Zhan P. Ju H, et al. Among authors: loregian a. J Med Chem. 2021 Dec 23;64(24):17992-18009. doi: 10.1021/acs.jmedchem.1c01366. Epub 2021 Nov 4. J Med Chem. 2021. PMID: 34735766
112 results